IOLCP Q1 FY27 Results: Revenue up 37%, PAT up 90% YoY

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

IOLCP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹167.50

prior close

₹170.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-2.0% vs market

Pharmaceuticals peers, median of 165sector-0.1%-2.0% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.8

10m

-0.7

15m

-0.3

30m

-2.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1-0.1-2.0-0.1-2.0

Next day

-2.2-0.2-2.0+0.0-2.2

-5.6+0.1-5.7-0.0-5.5

-0.9+0.3-1.2+0.3-1.2

-0.6+0.4-1.0-0.6-0.0

-3.8+0.5-4.3-1.1-2.7

-6.0+0.3-6.3-1.8-4.2

15d

+15.8+1.9+14.0+0.1+15.7

+26.6+2.2+24.4+1.4+25.2

+17.3-1.2+18.4-2.0+19.3

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

IOLCP Q1 FY27 (quarter ended 30 June 2026): Revenue from operations rose 37% YoY to Rs 756.26 Cr from Rs 551.69 Cr. Total income was Rs 764.44 Cr. PAT jumped about 90% to Rs 64.48 Cr from Rs 33.96 Cr. PBT rose to Rs 86.77 Cr from Rs 45.54 Cr. EPS at Rs 2.20 vs Rs 1.16. Both Pharma and Chemical segments posted higher revenues and profits. Auditor issued an unmodified limited review opinion.

Likely market impact

Strong quarter with double-digit revenue and profit growth across both segments; positive earnings momentum for shareholders.